ERBB2 and breast cancer: T-DXd has demonstrated efficacy in animal models [9] in both HER2+ and HER2-low BC, driven by key differences such as the internalization of the ADC prior to undergoing the degradation of the linker and a membrane-permeable payload, which allows for the release of the cytotoxic to the surrounding tumor, creating a “bystander” effect [10].